1. Airody A., Heath G., Lightman S., Gale R. Non-infectious uveitis: optimising the therapeutic response. Drugs. 2016; 76: 27 - 39. https://doi.org/10.1007/s40265-015-0502-y.

2. Barry R.G., Nguyen Q.D., Lee R.W. et al. Pharmacotherapy for uveitis: current management and emerging therapy. Clin Ophthalmol. 2014; 8: 1891 - 1911. doi: 10.2147/OPTH.S47778.

3. Лисицына Т.А., Алекберова З.С., Давыдова Г.А. и др. Современные представления о терапии увеитов при иммувоспалительных ревматических заболеваниях. Научно-практическая ревматология. 2020; 58(4): 428 - 436. doi: 10.47360/1995-4484-2020-428-436.

4. Merida S., Palacios E., Amparo N., Bosch-Morell F. New Immunosuppressive Therapies in Uveitis Treatment. Int JMolSci. 2015; 16(8): 18778 - 18795. doi: 10.3390/ijms160818778

5. Панова И.Е., Дроздова Е.А., Авдеева О.Н. Глава 28. Увеиты. В кн.: Офтальмология: национальное руководство / под ред. С.Э. Аветисова, Е.А. Егорова, Л.К. Мошетовой, В.В. Нероева, Х.П. Тахчиди. М.: ГЭОТАР-Медиа, 2018; С. 507 - 560.

6. Pasadhika S., Rosenbaum J.T. Update on the use of systemic biologic agents in the treatment of noninfectious uveitis. Biologics. 2014; 8: 67 - 81. doi: 10.2147/BTT.S41477.

7. Prete M., Dammacco R., Fatone M.C., Racanelli V. Autoimmuneuveitis: clinical, pathogenetic, and therapeutic features. ClinExpMed. 2016; 16(2): 125 - 36. doi: 10.1007/s10238-015-0345-6.

8. de Smet M.D., Taylor S.R., Bodaghi B., et al. Understanding uveitis: the impact of research on visual outcomes. Prog.Retin.EyeRes. 2011; 30(6): 452 - 470. https://doi.org/10.1016/j.preteyeres.2011.06.005

9. Lin P., Suhler E.B., Rosenbaum J.T. The future of uveitis treatment. Ophthalmology. 2014; 121: 365 - 376. https://dx.doi.org/10.1016%2Fj.ophtha.2013.08.029.

10. Agrawal R. Iyer J., Connolly J. et al. Cytokines and biologics in non-infectious autoimmune uveitis: bench tobedside. Indian J Ophthalmol. 2014; 62(1): 74 - 81. doi: 10.4103/0301-4738.126187.

11. Boyd S.R., Young S., Lightman S. Immunopathology of the noninfectious posterior andintermediate uveitides. Surv. Ophthalmol. 2011; 46: 209 - 233. https://doi.org/10.1016/s0039-6257(01)00275-2.

12. Дроздова Е.А., Теплова С.Н. Роль нарушения процессов регуляции иммунного ответа в патогенезе увеита, ассоциированного с ревматическими заболеваниями. Вестник офтальмологии. 2008; 124(3): 23 - 26.

13. Egwuagu C.E., Alhakeem S.A., Mbanefo E.C. Uveitis: molecular pathogenesis and emerging therapies. Front. Immunol. https://doi.org/10.3389/fimmu.2021.623725

14. Lee R.W.J., Dick A.D. Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation. Eye (Lond); 2012; 26(1): 17 - 28. doi: 10.1038/eye.2011.255.

15. Muhaya M. Characterization of phenotype and cytokine profiles of T cell lines derived from vitreous humour in ocular inflammation in man. Clin Exp Immunol. 1999; 16: 410 - 414. https://dx.doi.org/10.1046%2Fj.1365-2249.1999.00921.x.

16. Acharya N.R., Tham V.M., Esterberg E. et al. Incidence and prevalence of uveitis: resultsfrom the Pacific Ocular Inflammation Study. JAMA Ophthalmol. 2013; 131(11): 1405 - 1412. https://doi.org/10.1001/jamaophthalmol.2013.4237.

17. Durrani O.M., Meads C.A., Murray P.I. Uveitis: apotentially blinding disease. Ophthalmologica. 2004; 218(4): 223 - 36. doi: 10.1159/000078612.

18. Edelsten C, Reddy MA, Stanford MR, Graham EM. Visual loss associated with pediatric uveitis in English primary and referral centers. Am J Ophthalmol 2003; 135: 676 - 680.

19. Hsu Y. R. et al. Noninfectious uveitis in the Asia-Pacific region //Eye. - 2019. - Т. 33. - N. 1. - С. 66 - 77.

20. London N.J., Rathinam S.R., Cunningham E.T. Jr. The epidemiology of uveitis in developing country. Int. Ophthalmol. Clin. 2010; 50(2): 1 - 17. https://doi.org/10.1097/iio.0b013e3181d2cc6b

21. Miserocchi E., Fogliato G., Modorati G., Bandello F. Review on the world wide epidemiology of uveitis. Eur J Ophthalmol. 2013; 23(5): 705 - 717. https://doi.org/10.5301/ejo.5000278.

22. T, Tuominen J, Saari KM. Uveitis in children: population-based study in Finland. Acta Ophthalmol Scand 2000; 78: 84 - 88.

23. Siiskonen M., Hirn I., R. et al. Prevalence, incidence and epidemiology of childhood uveitis. Acta Ophthalmol. 2021; 99(2): e160 - e163. https://doi.org/10.1111/aos.14535

24. Nussenblatt R.B., Whitcup S.M. Uveitis: fundamentals and clinical practice, 4rded. Philadelphia: Mosby, 2010. - 433 с.

25. Конькова А.Ю., Гаврилова Т.В., Черешнева М.В. Состояние заболеваемости увеитами в Пермском крае. Вестник Совета молодых ученых и специалистов Челябинской области. 2015; 4(11), Т2: 31 - 35.

26. Shin Y., Kang Ji-M., Junwon Lee et al. Epidemiology of pediatric uveitis and associated systemic diseases. Pediatric Rheumatology 2021; 19: 48. https://doi.org/10.1186/s12969-021-00516-2

27. Smith J.A., Mackensen F., Sen H.N. et al., Epidemiology and course of disease in childhood uveitis. Ophthalmology. 2009; 116(8): 1544 - 51, doi: 10.1016/j.ophtha.2009.05.002.

28. BenEzra D, Cohen E, Maftzir G Uveitis in children and adolescents. Br J Ophthalmol. 2005 Apr; 89(4): 444 - 8. doi: 10.1136/bjo.2004.050609.

29. de Boer J., Wulffraat N., Rothova A. Visual loss in uveitis of childhood Br J Ophthalmol. 2003; 87(7): 879 - 84. doi: 10.1136/bjo.87.7.879.

30. Heiligenhaus A., Niewerth M., Ganser G. et al. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population based nation white study in Germany: suggested modification of the current screening guidelines. Rheumatology. 2007; V. 46. P. 1015 - 19.

31. Kotaniemi K., Kautiainen H., Karma A., Aho K. Occurrence of uveitis in recently diagnosed juvenile chronic arthritis: a prospective study. Ophthalmology. 2001; V. 108 (11): P. 2071 - 75.

32. Jabs D.A., Nussenblatt R.B., Rosenbaum J.T. Standardization of uveitis nomenclature (SUN) for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. - 2005; 140(3): 509 - 516. https://doi.org/10.1016/j.ajo.2005.03.057.

33. Jabs D.A., Busingye J. Approach to the diagnosis of the uveitides. Am J Ophthalmol. 2013; 56(2): 228 - 236. https://doi.org/10.1016/j.ajo.2013.03.027.

34. Астахов Ю.С., Кузнецова Т.И. Значение лазерной фотометрии в клинической практике. Офтальмол. ведомости. 2016: 2: 36 - 44. https://doi.org/10.17816/OV9236-44.

35. Davis J.L., Dacanay L.M., Holland G.N. et al. Laser flare photometry and complications ofchronic uveitis in children. Am J Ophthalmol. 2003; 135(6): 763 - 71. doi: 10.1016/s0002-9394(03)00315-5.

36. Tugal-TutkunI., Herbort C.P. Laser flarephotometry: anoninvasive, objective, and quantitative method to measure intraocular inflammation. Int Ophthalmol. 2010; 3: 453 - 464. https://doi.org/10.1007/s10792-009-9310-2

37. Nussenblatt R.B., Palestine A.G., Chan C.C., Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985; 92: 467 - 471. https://doi.org/10.1016/s0161-6420(85)34001-0.

38. Астахов Ю.С., Кузнецова Т.И., Хрипун К.В. и др. Перспективы диагностики и эффективность лечения болезни Фогта-Коянаги-Харада. Офтальмологические ведомости. 2014; 7(3): 84 - 92. https://doi.org/10.17816/OV2014384-92.

39. Ahnood D., Madhusudhan S., Tsaloumas M.D. et al. Punctate inner choroidopathy: a review. Survey of Ophthalmology 62(2). DOI: 10.1016/j.survophthal.2016.10.003

40. Катаргина Л.А., Денисова Е.В., Старикова А.В., Гвоздюк Н.А. Клинические особенности и результаты лечения увеитов, ассоциированных с синдромом Фогта-Коянаги-Харада у детей. Офтальмологические ведомости. 2012; 5(1): 36 - 43.

41. Crawford C.M., Okezie I. A review of the inflammatory chorioretinopathies: the white dot syndromes. ISRN Inflamm. 2013: 783190. doi: 10.1155/2013/783190.

42. Катаргина Л.А., Денисова Е.В., Старикова А.В. и др. Увеиты при болезни Бехчета у детей. Анализ литературы и описание случаев. Российская педиатрическая офтальмология. 2014; 1: 17 - 22.

43. Palejwala N.V., Walia H.S., YehS. Ocular manifestations of systemic lupus erythematosus: a review of the literature. Autoimmune Diseases. 2012; Article ID 290898 https://doi.org/10.1155/2012/290898.

44. Tugal-Tutkun I., Onal S., Altan-Yaycioglu R. et al. Uveitis in disease: an analysis of 880 patients. Am J Ophthalmol. 2004; 138(3): 373 - 80. doi: 10.1016/j.ajo.2004.03.022.

45. SfiniadakiE., TsiaraI., TheodossiadisP., ChatziralliI. Ocular Manifestations of Granulomatosis with Polyangiitis: A Review of the Literature. Ophthalmol Ther. 2019; 8(2): 227 - 234. doi: 10.1007/s40123-019-0176-8.

46. Дроздова Е.А., Ильинская Е.В. Диагностические возможности исследования оболочек глаза при увеитах. Медицинский вестник Башкортостана. 2018; 1(73): 51 - 54.

47. Устинова Е.И. Увеальная (воспалительная и послевоспалительная) глаукома (патогенез, клиника, классификация, лечение) //Офтальмологические ведомости. - 2009. - Т. 2. - N. 2. - С. 81 - 91.

48. Дроздова Е.А. Вторичная увеальная глаукома при системных заболеваниях //Глаукома. - 2005. - N. 2. - С. 19 - 23.

49. Regatieri C.V., Alwassia A., Zhang J.Y. et al. Use of optical coherence tomography in the diagnosis and management of uveitis. Int Ophthalmol Clin. 2012; 52(4): 33 - 43. https://doi.org/10.1097/iio.0b013e318265d439.

50. Herbort C.P. Fluorescein and indocyanine green angiography for uveitis. Middle East Afr J Ophthalmol. 2009; 16(4): 168 - 187. doi: 10.4103/0974-9233.58419

51. Khairallah M., Jelliti B. Fluorescein angiography in uveitis. Acta Ophthalmologica. 2011. https://doi.org/10.1111/j.1755-3768.2011.4231.x

52. Cimino L., Auer C., Herbort C.P. Sensitivity of indocyanine green angiography for the follow-up of active inflammatory choriocapillaropathies. Ocul Immunol Inflamm. 2000; 8(4): 275 - 283. https://doi.org/10.1076/ocii.8.4.275.6462.

53. Durrani K., Foster C.S. Fundus auto fluorescence imaging inposterior uveitis. Semin Ophthalmol. 2012; 27(5 - 6): 228 - 35. doi: 10.3109/08820538.2012.711414.

54. Lee C.S., Lee A.Y., Forooghian F. etal. Fundus auto fluorescence features in the inflammatory maculopathies. Clin Ophthalmol. 2014; 8: 2001 - 2012. doi: 10.2147/OPTH.S68446.

55. Moschos M.M., Gouliopoulos N.S., Kalogeropoulos C. Electrophysiological examination inuveitis: a review of the literature. Clin Ophthalmol. 2014; 8: 199 - 214. doi: 10.2147/OPTH.S54838.

56. Diwo E., P., Trad S. et al. Avis pour le traitement des non infectieuses [Therapeutic strategy for the treatment of non-infectious uveitis proposed by an expert panel]. Rev Med Interne. 2018 Sep; 39(9): 687 - 698. French. doi: 10.1016/j.revmed.2018.03.001

57. Criteria for diagnosis of disease. International Study Group for Disease. Lancet. 1990 May 5; 335(8697): 1078 - 80.

58. Herbort C.P., Rao N.A., Mochizuki M. International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop On Ocular Sarcoidosis (IWOS) Ocul Immunol Inflamm May - Jun 2009; 17(3): 160 - 9. doi: 10.1080/09273940902818861.

59. Read R.W., Holland G.N., Rao N.A. et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001; 131(5): 647 - 52. doi:10.1016/s0002-9394(01)00925-4.

60. Adams TN, Zhang D, Batra K, Fitzgerald JE. Pulmonary manifestations of large, medium, and variable vessel vasculitis. Respir Med. 2018 Dec; 145:182 - 191. doi: 10.1016/j.rmed.2018.11.003.

61. Kilic H. et al. Frequency of lung disease in patients diagnosed with uveitis //Erciyes Medical Journal. - 2015. - Т. 37. - N. 1. doi: http://doi.org/10.5152/etd.2015.8488

62. Панова, И.Е., Варнавская Н.Г., Самкович Е.В. Саркоидоз органа зрения как клиническое проявление мультиорганного поражения. //Вестник офтальмологии. - 2018. - N 434.5. - С. 32 - 38.

63. Годзенко А.А. и др. Поражение сердца при анкилозирующем спондилите //Научно-практическая ревматология. - 2009. - N. 4. - С. 4 - 10.

64. Angeles-Han S.T. Ringold S., Beukelman T. Et al. 2019 American college of rheumatology/arthritis foundation guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis-associated uveitis. Arthritis Rheumatol. 2019; 71(6): 864 - 877. doi: 10.1002/art.40885

65. Bou R., A., F. et al. Clinical management algorithm of uveitis associated with juvenile idiopathic arthritis: interdisciplinary panel consensus. Rheumatol Int. 2015; 35(5): 777 - 85. doi: 10.1007/s00296-015-3231-3.

66. Constantin T., Foeldvari I., Anton J., de Boer J., Czitrom-Guillaume S., Edelsten C. et al. Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative. Ann Rheum Dis. 2018 Aug; 77(8): 1107 - 1117. doi: 10.1136/annrheumdis-2018-213131.

67. Cunningham E.T., Wender J.D. Practical approach to the use of corticosteroids in patients with uveitis. Can J Ophthalmol. 2010. N 45(4). - P. 352 - 358. (https://doi.org/10.3129/i10-081).

68. Takeuchi M., Kanda T., Kaburaki T., Tanaka R., Namba K., Kamoi K., Maruyama K., Shibuya E., Mizuki N. Real-world evidence of treatment for relapse of noninfectious uveitis in tertiary centers in Japan: A multicenter study. Medicine (Baltimore). 2019. N 98(9): e14668. doi: 10.1097/MD.0000000000014668

69. Salek SS, Leder HA, Butler NJ, et al. Periocular triamcinolone acetonide injections for control of intraocular inflammation associated with uveitis. Ocul Immunol Inflamm 2013; 21: 257 - 263.

70. Денисова Е.В., Никишина И.П., Храброва М.А. Современный алгоритм скрининга, лечения и мониторинга увеита у детей с ювенильным идиопатическим артритом. Российская педиатрическая офтальмология. 2021; 15(1): 36 - 44.

71. Диагностика и лечение увеитов, ассоциированных с ювенильным идиопатическим артритом. Федеральные клинические рекомендации. Российская педиатрическая офтальмология. 2016; 11(2): 102 - 111.

72. HeiligenhausA., MindenK., TappeinerC. etal. Update of the evidence based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Semin Arthritis Rheum. 2019: 49(1): 43 - 55. doi: 10.1016/j.semarthrit.2018.11.004.

73. Jabs D.A., Rosenbaum J.T., Foster C.S. et al. Guidelines for the use of immuno suppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. AmJOphthalmol. 2000; 130(4): 492 - 513. https://doi.org/10.1016/s0002-9394(00)00659-0.

74. Bratton M.L., He Yu-G., Weakley D.R. Dexamethasone intravitreal implant (Ozurdex) for the treatment of pediatric uveitis. JAAPOS. 2014; 18(2): 110 - 3. doi: 10.1016/j.jaapos.2013.11.014.

75. E., Celemler P., Kimyon G. Intravitreal dexamethasone implant for treatment of refactory posterior uveitis: one-yearfollow-upresults. Ocul Immunol Inflamm. 2015; 23(6): 437 - 43. doi: 10.3109/09273948.2015.1042167.

76. A., Caspers L., Makhoul D. et al. Single Dexamethasone Intravitreal Implant in the Treatment of Noninfectious Uveitis. J Ocul Pharmacol Ther. 2017; 33(4): 290 - 297. https://doi.org/10.1089/jop.2016.0139.

77. Инструкция по медицинскому применению лекарственного препарата "Озурдекс" от 28.03.2016.

78. Khurana R.N., Porco T.C. Efficacy and safety of dexamethasone intravitreal implant for persistent uveitic cystoid macular edema. Retina. 2015; 35(8): 1640 - 6. doi: 10.1097/IAE.0000000000000515.

79. Lowder C., BelfortR. Jr, LightmanS. et al. HURON Study Group. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011; 129(5): 545 - 553. https://doi.org/10.1001/archophthalmol.2010.339

80. Tomkins-Netzer O., Talat L., Seguin-Greenstein S. etal. Outcome of treating pediatric uveitis with dexamethasone implants. Am J Ophthalmol. 2016 Jan; 161: 110 - 5. e1 - 2. doi: 10.1016/j.ajo.2015.09.036.

81. Tomkins-Netzer O., Taylor S.R., Bar A. et al. Treatment with repeat dexamethasone implantsresults in long-term disease control in eyes with noninfectious uveitis. Ophthalmology. 2014; 121(8): 1649 - 54. doi: 10.1016/j.ophtha.2014.02.003.

82. Zarranz-Ventura J., E., Johnston R.L. etal. Multicenter study of intravitreal dexamethasone implant in noninfectious uveitis: indications, outcomes, and reinjection frequency. Am J Ophthalmol. 2014; 158: 1136 - 1145. https://doi.org/10.1016/j.ajo.2014.09.003

83. Hassan M. et al. New therapies in development for the management of non-infectious uveitis: a review //Clinical & Experimental Ophthalmology. - 2019. - Т. 47. - N. 3. - С. 396 - 417.

84. Дугина А.Е. Победить воспаление: рациональное применение НПВС в офтальмологии //РМЖ. Клиническая офтальмология. - 2015. - Т. 16. - N. 3. - С. 139 - 145.

85. Максимов М.Л. и др. Возможности применения бромфенака в офтальмологической практике //РМЖ. Клиническая офтальмология. - 2021. - Т. 21. - N. 4. - С. 241 - 248.

86. Garcia Del Valle I., Alvarez-Lorenzo C. Atropine in topical formulations for the management of anterior and posterior segment ocular diseases //Expert Opinion on Drug Delivery. - 2021. - Т. 18. - N. 9. - С. 1245 - 1260.

87. Dodds E. M. Treatment strategies in patients with anterior uveitis //International Ophthalmology Clinics. - 2000. - Т. 40. - N. 2. - С. 55 - 68.

88. Синдром красного глаза (клиника, диагностика, лечение) / Егоров В.В., Смолякова Г.П., Сорокин Е.Л., Лузьянина В.В. - Хабаровск: Изд. Центр ИПКСЗ, 2007. - 175 с.

89. Eze U. A., Nathaniel G. I., Pepple G. Ophthalmic Uses of Atropine: A Review //J Adv Med Med Res. - 2022. - Т. 34. - N. 22. - С. 197 - 205.

90. Takeuchi M. et al. Evaluation of efficacy and safety of latanoprost/timolol versus travoprost/timolol fixed combinations for ocular hypertension associated with uveitis //Ocular Immunology and Inflammation. - 2017. - Т. 25. - N. 1. - С. 105 - 110. doi: 10.3109/09273948.2015.1092559.

91. Horsley M. B., Chen T. C. The use of prostaglandin analogs in the uveitic patient //Seminars in ophthalmology. - Taylor & Francis, 2011. - Т. 26. - N. 4 - 5. - С. 285 - 289.

92. Mahajan D., Venkatesh P., Garg S. P. Uveitis and glaucoma: a critical review //Journal of Current Glaucoma Practice. - 2011. - Т. 5. - N. 3. - С. 14 - 30.

93. Катаргина Л.А., Шестова Ю.П., Денисова Е.В. Синдром сухого глаза при эндогенных увеитах у детей. Российская педиатрическая офтальмология. 2012; 2: 17 - 20.

94. Kotaniemi K.M., Salomaa P.M., Sihto-Kauppi K. et al., An evaluation of dry eye symptomsand signs in a cohort of children with juvenile idiopathic arthritis. Clin Ophthalmol. 2009; 3: 271 - 275. http://doi.org/10.2147/opth.s4916.

95. Bose T., Diedrichs- M., Wildner G. Dry eye disease and uveitis: A closer look at immune mechanisms in animal models of two ocular autoimmune diseases //Autoimmunity reviews. - 2016. - Т. 15. - N. 12. - С. 1181 - 1192.

96. Лучихина Е.Л. Циклоспорин А при ревматоидном артрите: современные данные //Современная ревматология. - 2009. - N. 3. - С. 39 - 44.

97. Дроздова Е.А. Иммуносупрессивная терапия неинфекционных увеитов и ретиноваскулитов / / Офтальмология. - 2012 2014. - Т. 9. - N 2. - С. 58 - 61.

98. Vitale A.T., Rodriguez A., Foster C.S. Low-dose cyclosporine therapy in the treatment of birds hotretinochoroidopathy. Ophthalmology. 1994; 101(5): 822 - 31. doi: 10.1016/s0161-6420(13)31254-8.

99. Pilly B. et al. Overview and recent developments in the medical management of paediatric uveitis //Expert opinion on pharmacotherapy. - 2013. - Т. 14. - N. 13. - С. 1787 - 1795.

100. Levy-Clarke G., Jabs D.A., Read R.W. et al. Expert panel recommendations for the use ofanti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014; 21(3): 785 - 836. https://doi.org/10.1016/j.ophtha.2013.09.048

101. Khan I.J., Barry R.J., Amissah-Arthur K.N. etal. Ten-year experience of pulsedintravenous cyclophosphamide and methylprednisolone protocol (PICM protocol) in severe ocular inflammatory disease. Br J Ophthalmol. 2013; 97(9): 1118 - 22. doi: 10.1136/bjophthalmol-2012-302130.

102. Kempen J.H., Altaweel M.M., Holbrook J.T. et al. Writing Committee for the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study Research Group. Association Between Long-Lasting Intravitreous Fluocinolone Acetonide Implantvs Systemic Anti-inflammatory Therapy and Visual Acuity at 7 Years Among Patients With Intermediate, Posterior, or Panuveitis. //JAMA. - 2017. - N 317(19). - P. 1993 - 2005. (https://doi.org/10.1001/jama.2017.5103)

103. Charkoudian L.D., Ying G-S., Pujari S.S. et al. High-dose intravenous corticosteroids for ocular inflammatory diseases. Ocul Immunol Inflamm. 2012; 20(2): 91 - 9. doi: 10.3109/09273948.2011.646382.

104. Liu D., Ahmet A., Ward L. et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013; 9(1): 30. https://doi.org/10.1186/1710-1492-9-30.

105. Ringe J. D. Кальций, витамин d и его метаболиты в лечении остеопороза, связанного с длительным приемом глюкокортикоидов //Остеопороз и остеопатии. - 2002. - N. 1. - С. 31 - 34

106. Жданова О.А. и др. Побочные эффекты глюкокортикостероидной терапии у детей и возможность фармакологической коррекции //Экспериментальная и клиническая фармакология. - 2017. - Т. 80. - N. 11. - С. 18 - 25.].

107. Dick A.D., Rosenbaum J.T., Al-Dhibi H.A. et al. Guidance on noncorticosteroid systemic immunomodulatory therapy in no ninfectious uveitis: fundamentals of care for uveitis (FOCUS) initiative. Ophthalmology. 2018; 125(5): 757 - 773. https://doi.org/10.1016/j.ophtha.2017.11.017

108. Binder A.I., Graham E.M., Sanders M.D. et al. Cyclosporin A inthetreatment of severe uveitis. Br J Rheumatol. 1987; 26(4): 285 - 91. doi: 10.1093/rheumatology/26.4.285.

109. Murphy C. C. et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis //Archives of ophthalmology. - 2005. - Т. 123. - N. 5. - С. 634 - 641.

110. Gerloni V., Cimaz R., Gattinara M. et al. Efficacy and safety profile of cyclosporin A in the treatment of juvenile chronic (idiopathic) arthritis. Results of a 10-year prospective study. Rheumatology (Oxford). 2001; 40(8): 907 - 13. doi: 10.1093/rheumatology/40.8.907.

111. Kilmartin D.J., Forrester J.V., Dick A D. Cyclosporin A therapy in refractory non-infectious childhood uveitis. Br J Ophthalmol. 1998; 82(7): 737 - 42. doi:10.1136/bjo.82.7.737.

112. Tappeiner C., Roesel M., Heinz C. et al. Limited value of cyclosporine A for the treatment of patients with uveitis associated with juvenile idiopathic arthritis. Eye (Lond). 2009; 23(5): 1192 - 8. doi: 10.1038/eye.2008.174.

113. Костик М.М. и др. Способна ли терапия метотрексатом предотвращать развитие увеита у пациентов с ювенильным идиопатическим артритом: результаты ретроспективного исследования //Вопросы современной педиатрии. - 2015. - Т. 14. - N. 4. - С. 477 - 482.

114. Жураева Г.Б. Эффективность метотрексата при лечении неинфекционных увеитов //Oriental renaissance: Innovative, educational, natural and social sciences. - 2023. - Т. 3. - N. 2. - С. 654 - 660.

115. Foeldvari I., Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2005 Feb; 32(2): 362 - 5.

116. Heiligenhaus A., Mingels A., Heinz C., Ganser G. Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication. EurJOphthalmol. 2007; 17(5): 743 - 8. doi: 10.1177/112067210701700509.

117. Holz F.G., Krastel H., Breitbart A. et al. Low-dose methotrexate treatment in noninfectiousuveitisresistanttocorticosteroids Ger J Ophthalmol. 1992; 1(3 - 4): 142 - 4.

118. Kaplan-MessasA., BarkanaY., AvniI., NeumannR. Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis. Ocul Immunol Inflamm. 2003; 11(2): 131 - 139. doi: 10.1076/ocii.11.2.131.15919.

119. Kim Y.-H., Ko M.-R., Ryu K.-C., Il-Hyok K. Management of chronic noninfectious uveitis with low-dose methotrexate. Researchsquare. 2021. doi: 10.21203/rs.3.rs-161087/v1.

120. Malik A.R., Pavesio C. The use of low dose methotrexate in children with chronic anteriorand intermediate uveitis Br J Ophthalmol. 2005; 89(7): 806 - 8. doi: 10.1136/bjo.2004.054239.

121. Rathinam S.R., Babu M., Thundikandy R. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for non infectious uveitis. Ophthalmology. 2014; 121(10): 1863 - 70. doi: 10.1016/j.ophtha.2014.04.023.

122. Samson C.M., Waheed N., Baltatzis S., Foster C.S. Methotrexate therapy for chronic non infectious uveitis: analysis of acaseseries of 160 patients. Ophthalmology. 2001; 108(6): 1134 - 1139. doi: 10.1016/s0161-6420(01)00576-0.

123. Shah S.S., Lowder C.Y., Schmitt M.A. et al. Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology. 1992; 99(9): 1419 - 1423. doi: 10.1016/s0161-6420(92)31790-7.

124. Simonini G., Paudyal P., Jones G.T. et al. Current evidence of methotrexate efficacy inchildhood chronic uveitis: a systematic review and meta-analysis approach Rheumatology (Oxford). 2013; 52(5): 825 - 31. doi: 10.1093/rheumatology/kes186.

125. Tirelli F., Zannin M.E., Vittadello F. Methotrexate monotherapy in juvenile idiopathic arthritis associated uveitis: myth or reality? OculImmunol Inflamm. 2021. https://doi.org/10.1080/09273948.2021.1951303.

126. Ferrara G, Mastrangelo G, Barone P, La Torre F, Martino S, Pappagallo G, Ravelli A, Taddio A, Zulian F, Cimaz R; Rheumatology Italian Study Group. Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting. Pediatr Rheumatol Online J. 2018 Jul 11; 16(1): 46. doi: 10.1186/s12969-018-0255-8. PMID: 29996864; PMCID: PMC6042421.

127. Goebel J.C., Roesel M., Heinz C. et al. Azathioprine as a treatment option for uveitis in patients with juvenile idiopathic arthritis. Br J Ophthalmol. 2011; 95(2): 209 - 13. doi: 10.1136/bjo.2009.173542.

128. Pasadhika S., Kempen J.H., Newcomb C.W. et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol. 2009; 148(4): 500 - 509. doi. org/10.1016/j.ajo.2009.05.008.

129. Saadoun D., Wechsler B., Terrada C. et al. Azathioprine in severe uveitis of disease Arthritis Care Res (Hoboken) 2010 Dec; 62(12): 1733 - 8. doi: 10.1002/acr.20308.

130. Yazici H., Pazarli H., Barnes C.G. A controlled trial of azathioprine in syndrome. N Engl J Med. 1990; 322(5): 281 - 5. doi: 10.1056/NEJM199002013220501.

131. Rathinam S. R. et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial //Jama. - 2019. - Т. 322. - N. 10. - С. 936 - 945.

132. Бирюкова А.А., Ширинский И.В. Использование статинов для лечения неинфекционного увеита //Российский иммунологический журнал. - 2019. - Т. 13. - N. 2 - 1. - С. 165 - 167.

133. Chang P.Y., Giuliari G.P., Shaikh M. et al. Mycophenolate mofetil monotherapy in the management of paediatric uveitis. Eye (Lond). 2011; 25(4): 427 - 35. doi: 10.1038/eye.2011.23.

134. Daniel E., Thorne J.E., Newcomb C.W. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol. 2010; 149(3): 423 - 32. e1 - 2. doi: 10.1016/j.ajo.2009.09.026.

135. Doycheva D., Deuter C., Stuebiger N. et al. Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol. 2007; 91(2): 180 - 4. doi: 10.1136/bjo.2006.094698.

136. Galor A., Jabs D.A., Leder H.A. etal. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology. 2008; 115(10): 1826 - 32. doi: 10.1016/j.ophtha.2008.04.026.

137. Rodriguez E.E.C., Sakata V.M., MeloCavalcanti D.C.T. et al. Mycophenolatemofetil as an immunomodulator in refractory noninfectious uveitis. Arq Bras Oftalmol. 2016; 79(6): 369 - 372. doi: 10.5935/0004-2749.20160105.

138. Sobrin L., Christen W., Foster C.S. Mycophenolate mofetil after methotrexate failure orintolerancein the treatment of scleritis and uveitis. Ophthalmology. 2008; 115(8): 1416 - 1421. doi: 10.1016/j.ophtha.2007.12.011.

139. Teoh S.C., Hogan A.C., Dick A.D., Lee R.W.J. Mycophenolate mofetil for the treatment ofuveitis. Am J Ophthalmol. 2008; 146(5): 752 - 60, 760. e1 - 3. doi: 10.1016/j.ajo.2008.03.004.

140. Biester S., Deuter C., Michels H. et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol. 2007; 91(3): 319 - 24. doi: 10.1136/bjo.2006.103721.

141. Bravo-Ljubetic L., Peralta-Calvo J., Noval S. et al. Adalimumab therapy for refractory childhood uveitis. JAAPOS. 2013; 17(5): 456 - 9. doi: 10.1016/j.jaapos.2013.06.009.

142. V., Blanco R., E. et al. Anti-TNF- therapy in patients with refractoryuveitis due to disease: a 1-year follow-up study of 124 patients. Rheumatology (Oxford). 2014; 53(12): 2223 - 31. doi: 10.1093/rheumatology/keu266.

143. Dobner B.C., Max R., Becker M.D. et al. A three-centre experience with adalimumab forthetreatmentofnon-infectiousuveitis. Br J Ophthalmol. 2013; 97(2): 134 - 138. doi: 10.1136/bjophthalmol-2011-301401.

144. C., M., Salom D. et al. Usefulness of Adalimumab in the Treatment of Refractory Uveitis Associated with Juvenile Idiopathic Arthritis. Mediators Inflamm. 2013; 2013: 560632. doi: 10.1155/2013/560632

145. Jaffe G.J., Dick A.D., A.P. et al. Adalimumab in Patients with Active Noninfectious Uveitis. N Engl J Med 2016; 375: 932 - 943. DOI: 10.1056/NEJMoa1509852.

146. Magli A., Forte R., Navarro P. Adalimumab for juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol. 2013 Jun; 251(6): 1601 - 6. doi: 10.1007/s00417-013-2275-x.

147. Нероев В.В., Катаргина Л.А., Денисова Е.В. и др. Эффективность генно-инженерных биологических препаратов в лечении увеитов, ассоциированных с ревматическими заболеваниями у детей. Научно-практическая ревматология. 2012; N 4: С. 91 - 5.

148. Quartier P., Baptiste A., Despert V. et al. ADJUVITE Study Group. ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis. Ann Rheum Dis 2018; 77: 1003 - 11. doi: 10.1136/annrheumdis-2017-212089.

149. Ramanan A.V., Dick A.D., Jones A.P. et al. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med 2017; 376: 1637 - 46. doi: 10.1056/NEJMoa1614160

150. Riancho-Zarrabeitia L., Calvo- V., Blanco R. et al. Anti-TNF- therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients. Semin Arthritis Rheum. 2015; 45(3): 361 - 8. doi: 10.1016/j.semarthrit.2015.05.010.

151. Rudwaleit M., E., Holck P. et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis. 2009; 68(5): 696 - 701. doi: 10.1136/ard.2008.092585.

152. Simonini, G., Taddio, A., Cattalini, M. et al. Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifierdrug: Adalimumabas starting anti-TNF- therapy in childhood chronic uveitis. Pediatr Rheumatol, 16 (2013). https://doi.org/10.1186/1546-0096-11-16/

153. Suhler E.B., A., A.P. Safety and efficacy of adalimumab in patients with non infectious uveitis in an ongoing open-label study: VISUAL III. Ophthalmology. 2018; 125(7): 1075 - 1087.

154. van Denderen C.J., Visman I.M., Nurmohamed M.T. etal. Adalimumab significantly reduces the recurrence rate of anterior uveitisin patients with ankylosing spondylitis. J Rheumatol. 2014; 41(9): 1843 - 8. doi: 10.3899/jrheum.131289.

155. Zannin M.E., BiroloC., Gerloni V.M. etal. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol. 2013; 40(1): 74 - 9. doi: 10.3899/jrheum.120583.

156. Correll C.K., Bullock D.R., Cafferty R.M., Vehe R.K. Safety of weekly adalimumab in the treatment of juvenileidiopathicarthritisand pediatric chronic uveitis. Clin Rheumatol 2018; 37: 549 - 53. doi: 10.1007/s10067-017-3890-4.

157. Artornsombudh P., Gevorgyan O., Payal A. et al. Infliximab treatment of patients with birdshotretino choroidopathy. Ophthalmology 2013; 120(3): 588 - 592. doi: 10.1016/j.ophtha.2012.05.048.

158. Kruh J.N., Yang P., Suelves A.M., Foster C.S. Infliximab for the treatment of refractory non infectious Uveitis: a study of 88 patients with long-term follow-up. Ophthalmology. 2014; 121(1): 358 - 364. doi: 10.1016/j.ophtha.2013.07.019.

159. Markomichelakis N., Delicha E., Masselos S. etal. A single infliximab infusion vs corticosteroids for acute panuveitis attacks in disease: a comparative 4-week study. Rheumatology (Oxford). 2011; 50(3): 593 - 597. doi: 10.1093/rheumatology/keq366.

160. Niccoli L., Nannini C., Benucci M. et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study. Rheumatology (Oxford). 2007; 46(7): 1161 - 4. doi: 10.1093/rheumatology/kem101.

161. Suhler E.B., Smith J.R., Wertheim M.S. et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol. 2005; 123(7): 903 - 912. doi: 10.1001/archopht.123.7.903

162. Takeuchi M., Kezuka T., Sugita S. et al. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in disease: a multicenter study. Ophthalmology. 2014; 121(10): 1877 - 84. doi: 10.1016/j.ophtha.2014.04.042.

163. Tugal-Tutkun I., Mudun A., Urgancioglu M. et al. Efficacy of infliximabin the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in disease: an open-label trial. Arthritis Rheum. 2005; 52(8): 2478 - 84. doi: 10.1002/art.21231.

164. Tugal-Tutkun I., Ayranci O., Kasapcopur O., Kir N. Retrospective analysis of children with uveitis treated with infliximab. JAAPOS. 2008; 12(6): 611 - 3. doi: 10.1016/j.jaapos.2008.08.007.

165. Yamada Y., Sugita S., Tanaka H. et al. Comparison of infliximab versus ciclosporin duringthe initial 6-month treatment period in disease. Br J Ophthalmol. 2010; 94(3): 284 - 8. doi: 10.1136/bjo.2009.158840.

166. Kahn P, Weiss M, Imundo LF, Levy DM. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology 2006; 113: 860 - 4.

167. Sukumaran S., Marzan K., Shaham B., Reiff A. High dose infliximab in the treatment of refractory uveitis: does dose matter? ISRNR heumatol. 2012; 2012: 765380. doi: 10.5402/2012/765380.

168. V., Blanco R., M. Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients. Semin Arthritis Rheum. 2016; 46(1): 95 - 101. doi: 10.1016/j.semarthrit.2016.03.002.

169. Miserocchi E., Modorati G., Pontikaki I. et al. Long-term treatment with golimumab for severe uveitis. Ocul Immunol In flamm. 2014; 22(2): 90 - 5. doi: 10.3109/09273948.2013.844265.

170. Palmou-Fontana N., V., J.L. et al. Golimumab in refractoryuveitis associated to juvenile idiopathic arthritis: multicentre study of 7 cases and literaturereview Clin Exp Rheumatol. 2018; 36(4): 652 - 657.

171. Lanz S., Seidel G., Skrabl-Baumgartner A. Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab //Pediatric Rheumatology. - 2021. - Т. 19. - N. 1. - С. 132.

172. Tosi G.M., Sota J., Vitale A.et al. Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis. Clin Exp Rheumatol. 2019; 37(4): 680 - 683.

173. V., Mesquida M., de la Maza M.S. et al. Certolizumab pegol, a new anti-tnf- inthe armamentarium against ocular inflammation. Ocul Immunol Inflamm. 2016; 24(2): 167 - 72. doi: 10.3109/09273948.2014.967779.\

174. Atienza-Mateo B., V., E. et al.Anti-interleukin 6 receptor to cilizumab in refractory uveitis as sociated with disease: multicentre retrospective study. Rheumatology (Oxford). 2018; 57(5): 856 - 864. doi: 10.1093/rheumatology/kex480.

175. V., M., Calvo I. et al. Anti-interleukin-6 receptor tocilizumab for severe juvenile idiopathic arthritis-associated uveitis refractory to anti-tumor necrosis factor therapy: a multicenter study of twenty-five patients. Arthritis Rheumatol. 2017; 69(3): 668 - 675. doi: 10.1002/art.39940

176. Mesquida M., Molins B., V. et al. Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema. Ophthalmology. 2014; 121(12): 2380 - 6. doi: 10.1016/j.ophtha.2014.06.050.

177. Papo M., Bielefeld P., Vallet H. et al. Tocilizumab in severe and refractory non-infectiousuveitis. Clin Exp Rheumatol. 2014; 32 (4Suppl84): S 75 - 9

178. Tappeiner C., Mesquida M., A. et al. Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2016; 43(12): 2183 - 2188. doi: 10.3899/jrheum.160231.

179. Vegas-Revenga N., V., Mesquida M. et al. Anti-IL6-receptor tocilizumab inrefractory and noninfectious uveitic cystoid macular edema: multicenter study of 25 patients. Am J Ophthalmol. 2019; 200: 85 - 94. doi: 10.1016/j.ajo.2018.12.019.

180. Wennink R.A.W., Kalinina Ayuso V., de Vries L.A. Tocilizumab as an effective treatment option in children with refractory intermediate and panuveitis. Ocul Immunol Inflamm. 2021; 29: 1, 21 - 25. doi: 10.1080/09273948.2020.1712431.

181. Burlo F, Tumminelli C, Pastore S, Stocco G, Curci D, M, Tommasini A, Taddio A. Subcutaneous tocilizumab in the management of non-infectious uveitis in children: a brief report. Pediatr Rheumatol Online J. 2023 Sep 12; 21(1): 99. doi: 10.1186/s12969-023-00883-y. PMID: 37700264; PMCID: PMC10496382.

182. Abdallah H, et al. Pharmacokinetic and pharmacodynamic analysis of subcutaneous tocilizumab in patients with rheumatoid arthritis from 2 randomized, controlled trials: SUMMACTA and BREVACTA. Journal of clinical pharmacology. 2017; 57(4): 459 - 468. doi: 10.1002/jcph.826.

183. Davatchi F., Shams H., Rezaipoor M. et al. Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study). Int J Rheum Dis. 2010; 13(3): 246 - 52. doi: 10.1111/j.1756-185X.2010.01546.x.

184. Heiligenhaus A., Miserocchi E., Heinz C. et al. Treatment of severe uveitis associated withjuvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology 2011; 50: 1390 - 4. doi: 10.1093/rheumatology/ker107.

185. Miserocchi E., Pontikaki I, Modorati G. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Autoimmun Rev. 2011; 11(1): 35 - 9. doi: 10.1016/j.autrev.2011.07.001.

186. Birolo C., Zannin M.E., Arsenyeva S. et al. Comparable efficacy of abatacept used as first-line or second-line biological agent for severe juvenile idiopathic arthritis-related uveitis. JRheumatol. 2016; 43(11): 2068 - 2073. doi: 10.3899/jrheum.151389.

187. Zulian F., Balzarin M., Falcini F. et al. Abatacept for severe anti-tumor necrosis factoralpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res (Hoboken). 2010; 62(6): 821 - 825.

188. Разумова И.Ю., Годзенко А.А. Нестероидные противовоспалительные препараты в лечении переднего увеита при спондилоартритах //Вестник офтальмологии. - 2020. - Т. 136. - N. 6. - С. 70 - 77

189. Балабанова Р.М. Анкилозирующий спондилит и коморбидность: безопасность длительного применения нимесулида //Современная ревматология. - 2017. - Т. 11. - N. 4. - С. 79 - 82.

190. Годзенко А.А., Разумова И.Ю., Бочкова А.Г. Клиническая оценка увеита и ее значение в диагностике спондилоартритов //Научно-практическая ревматология. - 2011. - N. 6. - С. 38 - 42.

191. Wanders A., van der Heijde D., Landewe R. et al. Nonsteroidal anti-inflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005; 52(6): 1756 - 65

192. Murthy S.I., Pappuru R.R., Latha K.M. et al. Surgical management in patient with uveitis.IndianJ Ophthalmol. 2013; 61(6): 284 - 290 doi: 10.4103/0301-4738.114103.

193. Ramamurthi S., Obi E.E., Dutton G.N., Ramaesh K. Management and clinical outcome of penetrating keratoplasty for long-term corneal changes in sympathetic ophthalmia. J Ophthalmol. 2011; 2011: 439025. doi: 10.1155/2011/439025

194. Hennein L., Lambert N.G., Chamberlain W. et al. Keratoplasty outcomes in patients with uveitis. Cornea. 2021; 40(5): 590 - 595. doi: 10.1097/ICO.0000000000002527.

195. Kump L. I. et al. Analysis of pediatric uveitis cases at a tertiary referral center //Ophthalmology. - 2005. - Т. 112. - N. 7. - С. 1287 - 1292. https://doi.org/10.1016/j.ophtha.2005.01.044

196. Mehta S., Linton M.M., Kempen J.H. Outcomes of cataract surgery in patients with uveitis: A systematic review and meta-analysis. // Am J Ophthalmol. - 2014. - N 158. - P. 676 - 692. (https://doi.org/10.1016/j.ajo.2014.06.018)

197. Yangzes S., Seth N.G., Singh R. et al. Long-term outcomes of cataract surgery in children with uveitis. IndianJOphthalmol. 2019; 67(4): 490 - 495. doi: 10.4103/ijo.IJO_846_18.

198. Катаргина Л.А., Денисова Е.В., Ибейд Б.Н.А., Храброва М.А. Результаты имплантации клапана Ахмеда у детей с постувеальной глаукомой. Российский офтальмологический журнал. 2021; 14(1): 30 - 34. https://doi.org/10.21516/2072-0076-2021-14-1-30-34.

199. Ramdas W.D., Pals J., Rothova A., Wolfs R.C.W. Efficacy of glaucoma drainage devices in uveitic glaucoma and a meta-analysis of the literature. //Graefes Arch Clin Exp Ophthalmol. 2019. - N 257(1). - P. 143 - 151. (https://doi.org/10.1007/s00417-018-4156-9).

200. Денисова Е.В., Ибейд Б.Н.А., Коголева Л.В. Факторы избыточной пролиферации при синустрабекулэктомии у детей с постувеальной глаукомой. Офтальмология. 2021; 18(2): 284 - 289 https://doi.org/10.18008/1816-5095-2021-2-284-289.

201. Trittibach P. et al. Vitrectomy for juvenile uveitis: prognostic factors for the long-term functional outcome //Eye. - 2006. - Т. 20. - N. 2. - С. 184 - 190.

202. Becker, M., Davis, J., 2005. Vitrectomy in the treatment of uveitis. Am. J. Ophthalmol. 2005; 140(6): 1096 - 105. doi: 10.1016/j.ajo.2005.07.017.

203. Chan N. S. W., Choi J., Cheung C. M. G. Pediatric uveitis //Asia-Pacific Journal of Ophthalmology. - 2018. - Т. 7. - N. 3. - С. 192 - 199. https://doi.org/10.22608/APO.2018116

204. Agarwal A., Invernizzi A., Singh R.B. etal. An update on inflammatory choroidal neovascularization: epidemiology, multimodalimaging, andmanagement. Journal of Ophthalmic In flammationand Infection. 2018; 8: 13 https://doi.org/10.1186/s12348-018-0155-6.

205. Oyeniran E. et al. Treatment Outcomes of Anti-VEGF Agents for Non-Infectious Uveitic Macula Edema //Investigative Ophthalmology & Visual Science. - 2022. - Т. 63. - N. 7. - С. 3210-A0436.

206. Шилкина Н.П., Спирин Н.Н., Дряженкова И.В. Диагностика и лечение поражений нервной системы при ревматических заболеваниях //Лечащий врач. - 2009. - N. 4. - С. 26 - 29.

207. Гусева М.Р. Нейропептидная терапия в детской офтальмологической практике //Российская педиатрическая офтальмология. - 2015. - Т. 10. - N. 1. - С. 11 - 17.

208. Donoso A. et al. Therapeutic uses of natural astaxanthin: An evidence-based review focused on human clinical trials //Pharmacological Research. - 2021. - Т. 166. - С. 105479.

209. Yadav U., Kalariya N., Ramana K. Emerging role of antioxidants in the protection of uveitis complications //Current Medicinal Chemistry. - 2011. - Т. 18. - N. 6. - С. 931 - 942.

210. Pillar S, Amer R. The association between vitamin D and uveitis: A comprehensive review. Surv Ophthalmol. 2022 Mar - Apr; 67(2): 321 - 330. doi: 10.1016/j.survophthal.2021.07.006.

211. Основы курортологии. Частная курортотерапия. Под редакцией В.А. Александрова. Санаторно-курортное лечение глазных заболеваний. С.И. Тальковский. Москва: Медгиз., 1958: 327 - 344.

212. Оковитов В.В. Методы физиотерапии в офтальмологии. М., 1999, 142 с.

213. Куприянова И.Н., Флягина В.И., Зайкова Е.Ю. Офтальмологические проявления системных заболеваний как междисциплинарная проблема //Евразийский Союз Ученых. - 2015. - N. 7 - 3 (16). - С. 61 - 65

214. Кузнецова Т.И., Астахов Ю.С. Можно ли сократить долю увеитов неясной этиологии? //Офтальмологические ведомости. - 2019. - Т. 12. - N. 3. - С. 21 - 30..].

215. Дроздова Е.А., Ядыкина Е.В. Клинические параллели течения увеита и артрита у пациентов с ювенильным идиопатическим артритом //Вестник Совета молодых ученых и специалистов Челябинской области. - 2014. - N. 1 (5). - С. 41 - 44

216. Годзенко А.А. и др. Течение и исходы увеита у больных анкилозирующим спондилитом //Научно-практическая ревматология. - 2014. - Т. 52. - N. 5. - С. 520 - 525.

217. Кундер Е.В. Рекомендации по ведению пациентов с аксиальным спондилоартритом //Известия Национальной академии наук Беларуси. Серия медицинских наук. - 2019. - Т. 16. - N. 1. - С. 117 - 128.].